Oppenheimer raised the firm’s price target on Savara (SVRA) to $9 from $8 and keeps an Outperform rating on the shares. Ahead of December 2025 BLA submission for MOLBREEVI, the firm continues to see a more than $1B opportunity for MOLBREEVI in aPAP following recent updated claims data giving line of sight to at least 1,000 patients by launch with 750 already identified.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- Savara’s Strategic Positioning and Market Readiness for Molbreevi’s Potential Launch
- Savara’s MOLBREEVI: Strong Phase 3 Data and Financial Positioning Signal High Approval Likelihood and Market Potential
- Savara price target lowered to $10 from $11 at Citizens JMP
- Savara reports Q3 EPS (14c), consensus (13c)
- Savara Hit with Class Action Over Molbreevi Misrepresentations